Shetty Yashashri C, Aithal Yashoda R, Katkar Janhavi, Naik Manali
Pharmacology and Therapeutics, Seth Gordhandas Sunderdas (GS) Medical College and King Edward Memorial (KEM) Hospital, Mumbai, IND.
Institutional Ethics Committee, Seth Gordhandas Sunderdas (GS) Medical College and King Edward Memorial (KEM) Hospital, Mumbai, IND.
Cureus. 2024 Feb 2;16(2):e53476. doi: 10.7759/cureus.53476. eCollection 2024 Feb.
Background The role of academia in clinical research has given rise to the concept of academic clinical trials (ACTs), which are vital in generating evidence. Through the implementation of the New Drugs and Clinical Trials Rules-2019 (NDCTR-2019) rules, the Institutional Ethics Committee (IEC) has obtained a quasi-regulatory role. The study aims to assess the challenges the IEC faced when processing, approving, and monitoring ACTs. The other objectives included the number of ACTs submitted to the IEC, as well as administrative, scientific, and ethical issues stated by the IEC and the Drug Controller General of India (DCGI) authorities. We also aimed to provide some insight into the type of decision made by IEC and DCGI - the delay or inconsistency between the queries. Methods This retrospective study was conducted in the IEC of a tertiary care hospital, Mumbai, Maharashtra, India. A comprehensive search of the IEC database was carried out by the study team, and only those protocols of ACTs submitted to IEC between January 2015 and December 2021 were included. The studies submitted between January 2015 and February 2019, i.e., before the release of NDCTR-2019, were classified as the "Before" category. All subsequently submitted protocols were grouped together as the "After" group. Descriptive statistics were used to represent the data, while comparison between the two timeframes were made using the Mann-Whitney U test with a level of significance at 5%. Results This six-year study showed that merely 1.4% (34/2400) trials fulfilled the criteria of an ACT. An increase in the ACT protocol submission was noted in the "After" group (20 vs. 14). Most ACTs were drug trials, with 67.6% (23/34) trials conducted majorly in the Department of Anesthesiology. There was a statistical increase in time query reply by the principal investigator to IEC and the time between submission and approval in the "After" group (p<0.05). IEC sent out 94 administrative, 565 scientific, and 216 ethical queries. On IEC monitoring, protocol deviations were noted; nonetheless, no ACTs reported protocol deviations or serious adverse events. Conclusions Since the implementation of NDCTR-2019, IEC has taken on a quasi-regulatory function, and there has been an increase in the caliber of IEC monitoring and adherence to ethical norms.
背景 学术界在临床研究中的作用催生了学术临床试验(ACTs)的概念,这对于生成证据至关重要。通过实施《2019年新药与临床试验规则》(NDCTR - 2019),机构伦理委员会(IEC)获得了准监管角色。本研究旨在评估IEC在处理、批准和监测ACTs时所面临的挑战。其他目标包括提交给IEC的ACTs数量,以及IEC和印度药品总监(DCGI)当局提出的行政、科学和伦理问题。我们还旨在深入了解IEC和DCGI做出的决策类型——询问之间的延迟或不一致。
方法 这项回顾性研究在印度马哈拉施特拉邦孟买一家三级护理医院的IEC进行。研究团队对IEC数据库进行了全面搜索,仅纳入2015年1月至2021年12月期间提交给IEC的ACTs方案。2015年1月至2019年2月(即NDCTR - 2019发布之前)提交的研究被归类为“之前”类别。所有随后提交的方案被归为“之后”组。使用描述性统计来呈现数据,同时使用曼 - 惠特尼U检验对两个时间框架进行比较,显著性水平为5%。
结果 这项为期六年的研究表明,仅有1.4%(34/2400)的试验符合ACTs标准。“之后”组中ACT方案提交有所增加(20例对14例)。大多数ACTs是药物试验,67.6%(23/34)的试验主要在麻醉科进行。“之后”组中主要研究者对IEC的时间询问回复以及提交与批准之间的时间有统计学上的增加(p<0.05)。IEC发出了94个行政询问、565个科学询问和216个伦理询问。在IEC监测中,注意到方案偏差;尽管如此,没有ACTs报告方案偏差或严重不良事件。
结论 自NDCTR - 2019实施以来,IEC承担了准监管职能,并且IEC监测的质量以及对伦理规范的遵守有所增加。